HDFN
MCID: HML054
MIFTS: 23

Hemolytic Disease Due to Fetomaternal Alloimmunization (HDFN)

Categories: Blood diseases, Fetal diseases, Rare diseases

Aliases & Classifications for Hemolytic Disease Due to Fetomaternal Alloimmunization

MalaCards integrated aliases for Hemolytic Disease Due to Fetomaternal Alloimmunization:

Name: Hemolytic Disease Due to Fetomaternal Alloimmunization 59
Hemolytic Disease of the Fetus and Newborn 59
Hdfn 59

Classifications:



External Ids:

ICD10 33 P55 P55.9
ICD10 via Orphanet 34 P55.0 P55.1 P55.8 more
Orphanet 59 ORPHA275938

Summaries for Hemolytic Disease Due to Fetomaternal Alloimmunization

MalaCards based summary : Hemolytic Disease Due to Fetomaternal Alloimmunization, also known as hemolytic disease of the fetus and newborn, is related to blood group, gerbich system and fetal erythroblastosis. An important gene associated with Hemolytic Disease Due to Fetomaternal Alloimmunization is SLC29A1 (Solute Carrier Family 29 Member 1 (Augustine Blood Group)). The drugs Darbepoetin alfa and Hematinics have been mentioned in the context of this disorder. Affiliated tissues include testes, breast and monocytes.

Related Diseases for Hemolytic Disease Due to Fetomaternal Alloimmunization

Diseases related to Hemolytic Disease Due to Fetomaternal Alloimmunization via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 20)
# Related Disease Score Top Affiliating Genes
1 blood group, gerbich system 11.4
2 fetal erythroblastosis 11.3
3 fetal edema 10.3
4 hydrops fetalis 10.3
5 bilirubin metabolic disorder 10.2
6 posttransplant acute limbic encephalitis 10.2
7 kernicterus 10.1
8 blood group--kell system 10.0
9 yemenite deaf-blind hypopigmentation syndrome 10.0
10 branchiootic syndrome 1 10.0
11 blood group, junior system 10.0
12 deficiency anemia 10.0
13 exanthem 10.0
14 respiratory failure 10.0
15 opioid abuse 10.0
16 thrombocytopenia 10.0
17 cerebral palsy 10.0
18 purpura 10.0
19 hemolytic anemia 10.0
20 hypoglycemia 10.0

Graphical network of the top 20 diseases related to Hemolytic Disease Due to Fetomaternal Alloimmunization:



Diseases related to Hemolytic Disease Due to Fetomaternal Alloimmunization

Symptoms & Phenotypes for Hemolytic Disease Due to Fetomaternal Alloimmunization

Drugs & Therapeutics for Hemolytic Disease Due to Fetomaternal Alloimmunization

Drugs for Hemolytic Disease Due to Fetomaternal Alloimmunization (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Darbepoetin alfa Approved, Investigational Phase 2, Phase 3 11096-26-7, 209810-58-2
2 Hematinics Phase 2, Phase 3
3 Antibodies Phase 2
4 Immunoglobulins Phase 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Randomized Controlled Trial on the Use of EPO to Reduce Top-up Transfusions in Neonates With Red Blood Cell Alloimmunization Treated With Intrauterine Transfusions Recruiting NCT03104426 Phase 2, Phase 3 Darbepoetin Alfa
2 A Multicenter, Open-label Study to Evaluate the Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of M281 Administered to Pregnant Women at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn (HDFN) Recruiting NCT03842189 Phase 2 M281
3 Clinical Professor of Shanghai Tongji Hospital Approved for marketing NCT02969174
4 A Multicenter, Prospective Observational Study to Characterize the Clinical Course of Pregnant Women and Children at High Risk for Early Onset Severe Hemolytic Disease of the Fetus and Newborn Recruiting NCT03755128

Search NIH Clinical Center for Hemolytic Disease Due to Fetomaternal Alloimmunization

Genetic Tests for Hemolytic Disease Due to Fetomaternal Alloimmunization

Anatomical Context for Hemolytic Disease Due to Fetomaternal Alloimmunization

MalaCards organs/tissues related to Hemolytic Disease Due to Fetomaternal Alloimmunization:

41
Testes, Breast, Monocytes, Kidney, B Cells

Publications for Hemolytic Disease Due to Fetomaternal Alloimmunization

Articles related to Hemolytic Disease Due to Fetomaternal Alloimmunization:

(show top 50) (show all 228)
# Title Authors PMID Year
1
Fatal hemolytic disease of the fetus and newborn caused by anti-Jra antibody: A case report and literature review. 38
31324575 2019
2
A case of mild HDFN caused by anti-C, anti-D, and anti-G: Diagnostic strategy and clinical significance of distinguishing anti-G from anti-D and anti-C. 38
31303507 2019
3
Heat elution: a modification of the Landsteiner-Miller method. 38
31246486 2019
4
Prevention of hemolytic transfusion reactions with intravenous immunoglobulin prophylaxis in U- patients with anti-U. 38
30861151 2019
5
Blood Donation During Pregnancy Due to Anti-Ku Hemolytic Disease of the Fetus and Newborn. 38
31089725 2019
6
Severe Fetal Hemolysis and Cholestasis Due to High-Titer Maternal IgG Anti-A Antibodies. 38
30872329 2019
7
Molecular Detection of Glycophorins A and B Variant Phenotypes and their Clinical Relevance. 38
30910255 2019
8
Identification of red blood cell antibodies in maternal breast milk implicated in prolonged hemolytic disease of the fetus and newborn. 38
30720868 2019
9
Anemic Disease of the Newborn With Little Increase in Hemolysis and Erythropoiesis Due to Maternal Anti-Jra: A Case Study and Review of the Literature. 38
31227265 2019
10
Transfusion-related red blood cell alloantibodies: induction and consequences. 38
30808636 2019
11
Postponing early intrauterine transfusion with intravenous immunoglobulin treatment: the PETIT study on severe hemolytic disease of the fetus and newborn. 38
30837065 2019
12
Hemolytic disease of the fetus and newborn due to alloanti-M: three Chinese case reports and a review of the literature. 38
30520533 2019
13
Bombay phenotype (Oh ) and high-titer anti-H in pregnancy: two case reports and a review of the literature. 38
30260479 2018
14
Sulfhydryl treatment of serum or plasma for the reduction of IgM antibodies. 38
30624946 2018
15
The first case of severe acute hemolytic transfusion reaction caused by anti-Sc2. 38
30299537 2018
16
Severe hemolytic disease of the fetus and newborn due to allo-anti-D in a patient with a partial DEL phenotype arising from the variant allele described as RHD*148+1T (RHD*01EL.31). 38
30222865 2018
17
Neonatal Alloimmune Neutropenia. 38
31049048 2018
18
Red Blood Cell Alloimmunization in the Pregnant Patient. 38
30097223 2018
19
Predicting anti-Kell-mediated hemolytic disease of the fetus and newborn: diagnostic accuracy of laboratory management. 38
30063902 2018
20
Postponing Early intrauterine Transfusion with Intravenous immunoglobulin Treatment; the PETIT study on severe hemolytic disease of the fetus and newborn. 38
29902448 2018
21
Clinical significance of antibodies to antigens in the Raph, John Milton Hagen, I, Globoside, Gill, Rh-associated glycoprotein, FORS, JR, LAN, Vel, CD59, and Augustine blood group systems. 38
30295501 2018
22
Clinical significance of antibodies to antigens in the Scianna, Dombrock, Colton, Landsteiner-Weiner, Chido/Rodgers, H, Kx, Cromer, Gerbich, Knops, Indian, and Ok blood group systems. 38
30295505 2018
23
Determination of fetal RHD type in plasma of RhD negative pregnant women. 38
29869532 2018
24
Predicted S and s phenotypes from genotyping results among Thai populations to prevent transfusion-induced alloimmunization risks. 38
30078741 2018
25
Frequency of Red Cell Alloantibodies in Pregnant Females of Navsari District: An Experience that Favours Inclusion of Screening for Irregular Erythrocyte Antibody in Routine Antenatal Testing Profile. 38
30065546 2018
26
ABO incompatibility and RhIG immunoprophylaxis protect against non-D alloimmunization by pregnancy. 38
29624682 2018
27
Transfusions of least-incompatible blood with intravenous immunoglobulin plus steroids cover in two patients with rare antibody. 38
29732576 2018
28
Molecular characterization and multidisciplinary management of Gerbich hemolytic disease of the newborn. 38
29469208 2018
29
Clinical significance of antibodies to antigens in the International Society of Blood Transfusion collections, 700 series of low-incidence antigens, and 901 series of high-incidence antigens. 38
29989417 2018
30
Molecular basis of weak D expression in the Indian population and report of a novel, predominant variant RHD allele. 38
29479713 2018
31
Evaluation of a Decision Tree for Efficient Antenatal Red Blood Cell Antibody Screening. 38
29337843 2018
32
Lessons learned from the implementation of non-invasive fetal RHD screening. 38
29616835 2018
33
A unique major histocompatibility complex Class II-binding register correlates with HLA-DR11-associated immunogenicity of the major K blood group antigen. 38
29464723 2018
34
A proposed new low-frequency antigen in the Augustine blood group system associated with a severe case of hemolytic disease of the fetus and newborn. 38
29504136 2018
35
ABO hemolytic disease of the fetus and newborn: thirteen years of data after implementing a universal bilirubin screening and management program. 38
29410540 2018
36
Jk3 alloantibodies during pregnancy-blood bank management and hemolytic disease of the fetus and newborn risk. 38
29479723 2018
37
Red blood cells, still vital after all these years: Commentary on Canadian Blood Services' International Symposium 2017. 38
29691151 2018
38
Successful management of severe red blood cell alloimmunization in pregnancy with a combination of therapeutic plasma exchange, intravenous immune globulin, and intrauterine transfusion. 38
29250791 2018
39
How shall we transfuse Hippolyta? 38
29097176 2018
40
Erythrocyte Saturation with IgG Is Required for Inducing Antibody-Mediated Immune Suppression and Impacts Both Erythrocyte Clearance and Antigen-Modulation Mechanisms. 38
29358275 2018
41
A new biosensor for noninvasive determination of fetal RHD status in maternal blood of RhD negative pregnant women. 38
29874251 2018
42
Management of pregnancy sensitized with anti-Inb with monocyte monolayer assay and maternal blood donation. 38
29608321 2018
43
The development of D antibodies after D-mismatched kidney transplantation in a setting of reduced immunosuppression. 38
29193117 2018
44
A brief overview of clinical significance of blood group antibodies. 38
29608320 2018
45
Rhesus blood group haplotype frequencies among blood donors in southwestern Uganda. 38
29950915 2018
46
Anti-Vel alloimmunization and severe hemolytic disease of the fetus and newborn. 38
29378146 2017
47
Prevention of hemolytic disease of the fetus and newborn: what have we learned from animal models? 38
28719385 2017
48
Persistence of Villous Immaturity in Term Deliveries Following Intrauterine Transfusion for Parvovirus B19 Infection and RhD-associated Hemolytic Disease of the Fetus and Newborn. 38
29187036 2017
49
D antibodies in pregnant women in multiethnic Suriname: the observational RheSuN study. 38
28703855 2017
50
A Guide to Terminology for Rh Immunoprophylaxis. 38
28796682 2017

Variations for Hemolytic Disease Due to Fetomaternal Alloimmunization

ClinVar genetic disease variations for Hemolytic Disease Due to Fetomaternal Alloimmunization:

6
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 SLC29A1 NM_001304463.1(SLC29A1): c.1285A> C (p.Thr429Pro) single nucleotide variant Pathogenic rs1131690802 6:44200643-44200643 6:44232906-44232906

Expression for Hemolytic Disease Due to Fetomaternal Alloimmunization

Search GEO for disease gene expression data for Hemolytic Disease Due to Fetomaternal Alloimmunization.

Pathways for Hemolytic Disease Due to Fetomaternal Alloimmunization

GO Terms for Hemolytic Disease Due to Fetomaternal Alloimmunization

Sources for Hemolytic Disease Due to Fetomaternal Alloimmunization

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....